Ibrutinib CAS 936563-96-1 Mama >99.5% (HPLC) API

Fa'amatalaga Puupuu:

Igoa vaila'au: Ibrutinib

CAS: 936563-96-1

Mama: >99.5% (HPLC)

Fa'aaliga: Pa'epa'e i le Pa'u tioata Pa'epa'e

Ibrutinib ose BTK inhibitor fa'aaogaina e togafitia ai Chronic Lymphocytic Leukemia (CLL) ma Mantle Cell Lymphoma (MCL)

Fa'afeso'ota'i: Dr. Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Auina imeli ia matou

Fa'amatalaga Oloa

Oloa Fa'atatau

Faailoga o oloa

Fa'amatalaga:

Ibrutinib Fesoʻotaʻi Faʻatasi:
(S)-1-Boc-3-Hydroxypiperidine CAS 143900-44-1
4-Phenoxyphenylboronic Acid CAS 51067-38-0
Ibrutinib Intermediate N-2 CAS 330786-24-8
Ibrutinib Intermediate N-3 CAS 330792-70-6
Ibrutinib CAS 936563-96-1

Meatotino tau vailaau:

Igoa Vailaau	Ibrutinib
Synonyms	1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1- tasi;PCI-32765
Numera CAS	936563-96-1
Tulaga Fa'asoa	I Fa'atauga, Oloa Fua e O'o i Tone
Fuafua mole	C25H24N6O2
Molecular Weight	440.50
Fa'ailoga	Ruifu Chemical

Fa'amatalaga:

Aitema	Fa'amatalaga
Fa'aaliga	Pa'epa'e i le Pa'u Pa'epa'e Pa'epa'e
Fa'ailoaga	IR;HPLC
Ma'imau ile Fa'amago	<0.50%
Toega i luga o le mumu	≤0.10%
Metala mamafa (pei o le Pb)	≤20ppm
So'o se Fa'aleaga Ta'itasi	≤0.20%
Aofa'i Fa'aleaga	<0.50%
Mama / Suʻesuʻega Metotia	>99.5% (HPLC)
Tulaga Su'ega	Pisinisi Tulaga
Fa'aoga	API

Paket & Teuina:

afifi: Fagu, Ato pepa alumini, 25kg/Kati Pusa, pe tusa ai ma manaoga o tagata faatau.

Tulaga teuina:Teu i totonu o pusa faʻamaufaʻailoga i se nofoaga malulu ma mago;Puipui mai le malamalama ma le susu.

Tulaga lelei:

FAQ:

Talosaga:

O le Ibrutinib (CAS: 936563-96-1) o se fa'alavelave ole Bruton tyrosine kinase (BTK) mo le togafitia o le leukemia lymphocytic masani (CLL) ma le lymphoma cell mantle (MCL).O le MCL ma le CLL e aofia uma i le B-cell non-Hodgkin's lymphoma, lea e le mafai ona toe foʻi.Ole chemoimmunotherapy e masani ona fa'aogaina e le o fa'atatauina, ma o le vasega 3 po'o le 4 e masani ona tupu mai ni fa'alavelave leaga.Ibrutinib e mafai ona tuʻufaʻatasia ma le BTK, lea e manaʻomia mo le faʻavaeina, faʻavasegaina, fesoʻotaʻiga ma le ola o B lymphocytes, ma faʻalavelave faʻafuaseʻi le gaioiga a le BTK, faʻamalosia lelei le faʻateleina ma le ola o sela tumo.E le gata i lea, e vave ona faʻaaogaina pe a uma le tautala tautala, o le maualuga o le plasma concentration e oʻo atu i le 1 ~ 2h, ma o faʻalavelave leaga o le vasega 1 poʻo le 2, lea o le a avea ma se filifiliga fou mo togafitiga o CLL ma MCL.I le aso 13 o Novema, 2013, na faʻavaveina ai e le US FDA le kamupani Johnson & Johnson ua faʻamaonia ma le United States Imbruvica (igoa masani: Ibrutinib) mo le togafitiga o le lymphoma sela (MCL).Ibrutinib, na tuʻuina atu i ai le tulaga faʻapitoa o togafitiga e le FDA ia Fepuari 2013 ma na faʻamaonia mo MCL i le aso 13 o Novema, 2013 ma le CLL i le aso 12 o Fepuari, 2014.